Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 7/20 | 0.67 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.67 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.67 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.67 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.57 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2537505 | 1.00 | PTGER4 (0.67) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL16585839 | 0.90 | PTGER4 (0.53) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL16585842 | 0.90 | PTGER4 (0.53) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL2541533 | 0.89 | PTGER4 (0.57) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL2541531 | 0.89 | PTGER4 (0.57) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL2540966 | 0.88 | PTGER4 (0.53) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL2540962 | 0.88 | PTGER4 (0.53) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL2537060 | 0.87 | PTGER4 (0.55) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL2532594 | 0.87 | PTGER4 (0.55) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL2532595 | 0.87 | PTGER4 (0.55) | PTGER4PTGER2PTGER3PTGER1LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3046902-B1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2018-08-08 | — | — | EP | disclosed |
| US-9630935-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2017-04-25 | — | — | US | disclosed |
| US-20160280671-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2016-09-29 | — | — | US | disclosed |
| EP-3046902-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | Vectus Biosystems Limited (AU) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015039172-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS PTY LTD (AU) | 2015-03-26 | — | — | WO | disclosed |
| US-8044236-B2 | Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| EP-2080751-A1 | CARBOXYLIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-20080275116-A1 | Carboxilic acid derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280671-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | TGFB1, REN, TGFB2 | PTGER4 133/4885PTGER2 82/4885PTGER3 150/4885 |
| US-20080275116-A1 | Carboxilic acid derivatives | SERPINE1, CTRL, SERPINC1 | PTGER4 3046/4885PTGER2 2944/4885PTGER3 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.